Health Economics›Myelodysplastic syndrome›First-line therapy

First-line therapy

Myelodysplastic syndrome · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alemtuzumab monotherapy Variant #01	—	R 132 218	7d	~15.0 mo	—	~66	~R 8 726 355 PFS proxy · indirect	—
ATG (Horse) monotherapy Variant #01	—	R 116 960	17d	—	—	—	—	—
ATG (Rabbit) monotherapy Variant #01	—	R 44 505	18d	—	—	—	—	—
Azacitidine and Lenalidomide Variant #01	—	R 20 877	28d	—	—	—	—	—
Azacitidine monotherapy Variant #01	—	R 18 699	28d	—	24.5 mo	—	—	1
Azacitidine and Vorinostat Variant #01 Partial	—	R 18 699	28d	—	—	—	—	—
Decitabine monotherapy Variant #01	—	R 10 907	42d	—	10.1 mo	—	—	1
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~4.0 mo	~16.3 mo	~5	~R 40 764 PFS proxy · indirect	10
Cyclosporine monotherapy Variant #03	—	R 2 156	—	—	—	—	—	—
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 172	28d	—	~5.4 mo	—	—	11
ATG (Horse) and Cyclosporine N/A - secondary systemic drug	—	R 109	—	—	—	—	—	—
Decitabine and cedazuridine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	1
Best supportive care Partial	—	—	—	—	11.8 mo	—	—	2

14 of 14 regimens shown